Cimzia (certolizumab pegol) (Subcutaneous
Coverage and utilization management policy for certolizumab pegol (Cimzia) for Medicaid, Commercial, and Medicare-Medicaid Plan (MMP) members; includes authorization length, quantity limits, dosing, indication-specific initial and renewal criteria, safety screening requirements, billing codes and covered diagnosis codes (appendix).
No material clinical or coverage changes noted in this update.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.